Abstract
Gastric cancer is the fourth most common cancer in the world and second most common reason for cancer related death. Projections for the future predict that gastric cancer incidence will continue to rise. Risk factors for gastric cancer are Helicobacter pylori (H pylori) infection, host genetic factors and environmental factors. H pylori is a class I carcinogen and responsible for 60 % - 80 % of all gastric cancers of intestinal and diffuse type, as well as gastric MALT lymphoma.
From animal and intervention studies we know that premalignant gastric lesions development and gastric cancer can be prevented with early H pylori eradication. In countries with gastric cancer incidence higher than 20 / 100 000 per year national screening for H pylori infection and eradication of all H pylori infections should be performed. Type of eradication therapy depends on local antimicrobial resistance rates. Quadruple bismuth or non- bismuth therapies can achive more than 90 % eradication rate. The success of eradication therapy must be controlled with noninvasive test.
Patients with extensive preneoplastic changes (atrophy, intestinal metaplasia) should have endoscopic and histologic controls. Endoscopic screening should be performed in intervals according to the risk stratification by OLGA / OLGIM staging system or A-D staging system.
In countries with high gastric cancer incidence national screening with serological tests for pepsinogen I (PGI), PGI/PGII ratio and H pylori antibodies can select patients at higher risk for gastric cancer.
Keywords: Gastric cancer, Helicobacter pylori, population based screening, therapy, endoscopic surveillance.
Current Pharmaceutical Design
Title:Population Based Helicobacter pylori Screening and Eradication: Advances Versus Side Effects
Volume: 20 Issue: 28
Author(s): Prof Bojan Tepes
Affiliation:
Keywords: Gastric cancer, Helicobacter pylori, population based screening, therapy, endoscopic surveillance.
Abstract: Gastric cancer is the fourth most common cancer in the world and second most common reason for cancer related death. Projections for the future predict that gastric cancer incidence will continue to rise. Risk factors for gastric cancer are Helicobacter pylori (H pylori) infection, host genetic factors and environmental factors. H pylori is a class I carcinogen and responsible for 60 % - 80 % of all gastric cancers of intestinal and diffuse type, as well as gastric MALT lymphoma.
From animal and intervention studies we know that premalignant gastric lesions development and gastric cancer can be prevented with early H pylori eradication. In countries with gastric cancer incidence higher than 20 / 100 000 per year national screening for H pylori infection and eradication of all H pylori infections should be performed. Type of eradication therapy depends on local antimicrobial resistance rates. Quadruple bismuth or non- bismuth therapies can achive more than 90 % eradication rate. The success of eradication therapy must be controlled with noninvasive test.
Patients with extensive preneoplastic changes (atrophy, intestinal metaplasia) should have endoscopic and histologic controls. Endoscopic screening should be performed in intervals according to the risk stratification by OLGA / OLGIM staging system or A-D staging system.
In countries with high gastric cancer incidence national screening with serological tests for pepsinogen I (PGI), PGI/PGII ratio and H pylori antibodies can select patients at higher risk for gastric cancer.
Export Options
About this article
Cite this article as:
Tepes Bojan Prof, Population Based Helicobacter pylori Screening and Eradication: Advances Versus Side Effects, Current Pharmaceutical Design 2014; 20 (28) . https://dx.doi.org/10.2174/13816128113196660733
DOI https://dx.doi.org/10.2174/13816128113196660733 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Organoselenium Compounds as Potential Neuroprotective Therapeutic Agents
Current Organic Chemistry Role of Moving Average Analysis for Development of Multi-Target (Q)SAR Models
Mini-Reviews in Medicinal Chemistry Cu-mediated synthesis of 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-1-ones as potential inhibitors of sirtuins
Letters in Drug Design & Discovery The Mechanisms of Anticancer Agents by Genistein and Synthetic Derivatives of Isoflavone
Mini-Reviews in Medicinal Chemistry Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders
Current Cancer Therapy Reviews Quantitative Structure-Activity Relationship Studies on Nitric Oxide Synthase Inhibitors
Current Enzyme Inhibition Xanthohumol: A Metabolite with Promising Anti-Neoplastic Potential
Anti-Cancer Agents in Medicinal Chemistry Erythropoietin Signaling and Neuroprotection
Current Signal Transduction Therapy Exercise for the Overweight and Obese
Current Pharmaceutical Design Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design
Current Topics in Medicinal Chemistry Wound Healing and Antimicrobial Potential of Oroxylum indicum Vent. in Albino Mice
The Natural Products Journal On the Involvement of H2S in Nitroso Signaling and Other Mechanisms of H2S Action
Current Pharmaceutical Biotechnology Pathophysiology and Pharmacological Targeting of Tumor-Induced Bone Disease: Current Status and Emerging Therapeutic Interventions
Current Medicinal Chemistry MYC-Mediated Synthetic Lethality for Treating Tumors
Current Cancer Drug Targets Actions of Adjunctive Nutritional Antioxidants in Periodontitis and Prevalent Systemic Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of E-Cadherin Down-Regulation in Oral Cancer: CDH1 Gene Expression and Epigenetic Blockage
Current Cancer Drug Targets Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death
Mini-Reviews in Medicinal Chemistry Identifying Molecular Biomarker for the Lung Squamous Cell Carcinoma by Integrating Multifactorial Data
Current Bioinformatics MARK1 is a Novel Target for miR-125a-5p: Implications for Cell Migration in Cervical Tumor Cells
MicroRNA Biomarkers of Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), A Review of Published Patents and Patent Applications
Recent Patents on Biomarkers